Advertisement

Topics

SGLT1/2 Inhibitor Sotagliflozin 'Encouraging' in Type 1 Diabetes

05:40 EDT 22 Jun 2017 | Medscape

The investigational, oral agent sotagliflozin, a first-in-class, oral dual inhibitor of both SGLT1 and SGLT2, is in phase 3 trials in type 1 diabetes; results are promising but there are some caveats.
Medscape Medical News

Original Article: SGLT1/2 Inhibitor Sotagliflozin 'Encouraging' in Type 1 Diabetes

NEXT ARTICLE

More From BioPortfolio on "SGLT1/2 Inhibitor Sotagliflozin 'Encouraging' in Type 1 Diabetes"

Advertisement
Quick Search
Advertisement
Advertisement